Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD

Is the neuroplastogen TSND-201 (methylone) efficacious and well tolerated in people with posttraumatic stress disorder (PTSD)?In this phase 2, double-blind, placebo-controlled randomized clinical trial in 65 people with severe PTSD, acute intermittent treatment with TSND-201 was associated with a statistically significant and clinically meaningful reduction in PTSD symptoms, measured by Clinician-Administered PTSD Scales for scores, compared with placebo. TSND-201 was generally safe and well tolerated; adverse events were typically transient, occurring on the day of dosing and resolving within a day.Study results demonstrate that TSND-201 has rapid, robust, and durable efficacy and is well tolerated in people with PTSD, supporting its further development as a treatment for PTSD.

Corresponding Author: Amanda Jones, PharmD, Transcend Therapeutics, 80 Fifth Ave, 18th Floor, New York, NY 10011 (amanda@transcendtherapeutics.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.